Flare Therapeutics

Flare Therapeutics

Private
Cambridge, MassachusettsHealthcare & Life Scienceswww.flaretx.com

Last Round

Series B

Mar 22, 2023

Total Funding Raised

$205M

Company Overview

Flare Therapeutics is a health-tech company that provides small-molecule precision medicine solutions for cancer patients, focusing on transcription factors to develop targeted treatments for neurology, rare genetic disorders, immunology, and inflammation.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Non-AI

Keywords

transcription factor targetingsmall molecule drugsdrug discovery platformundruggable targetsdrugging the undruggableprecision oncologyclinical-stage biotechswitch site discoveryFX-909urothelial cancerbladder cancerPPARG inhibitorpharma partnershipsAR degraderprostate cancerchemoproteomics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Flare Therapeutics Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Flare Therapeutics Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series BMar 22, 2023
Series AMay 13, 2021

Key People

Founding team and executive leadership

Robert Sims

Chief Scientific Officer, Co-founder

Founding Team

Flare Therapeutics Investors

Notable investors and investment history

InvestorRounds
Agent CapitalSeries B
Boxer CapitalSeries A, Series B
GordonMD Global InvestmentsSeries B
Eventide FundsSeries B, Series A
Invus OpportunitiesSeries B, Series A
Pavilion CapitalSeries B
Pfizer VenturesSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 6, 2026

    Presenting three posters at the AACR Annual Meeting 2026.

  • Feb 27, 2026

    Presented at the 2026 ASCO Genitourinary Cancers Symposium.

Flare Therapeutics Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Flare Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Flare Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range62
Year Founded2021
Last FundingMar 22, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.